Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834150 | 0.91 | HCAR2 (0.44) | HCAR2HDAC3HDAC1 | |
| SCHEMBL6834350 | 0.91 | ALDH1A1 (0.50) | PLK1PLK3HCAR2POLBMAPT | |
| SCHEMBL6834149 | 0.89 | HCAR2 (0.48) | PLK1PLK3HCAR2HDAC3HDAC1 | |
| SCHEMBL6834218 | 0.87 | HDAC3 (0.42) | POLBHDAC3HDAC1ALBKDM4E | |
| SCHEMBL6834088 | 0.86 | HDAC3 (0.46) | HCAR2POLBHDAC3HDAC1ALB | |
| SCHEMBL6835693 | 0.86 | POLB (0.47) | PLK1POLBHDAC3HDAC1ALB | |
| SCHEMBL6834023 | 0.86 | HCAR2 (0.43) | HCAR2KDM4E | |
| SCHEMBL7198190 | 0.86 | ALB (0.46) | PLK1PLK3RAB9AHCAR2HDAC1 | |
| SCHEMBL6833331 | 0.85 | PTPN2 (0.44) | PLK1PLK3POLBHDAC3HDAC1 | |
| SCHEMBL6833069 | 0.85 | POLB (0.48) | RAB9APOLBMAPTPPARDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | PLK1 4270/4885PLK3 3358/4885RAB9A 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.